Baylor Genetics Wins BioTech Breakthrough Award
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic…
Synata Bios Sylonto Project Awarded $4.5 Million NDRC Grant
WARRENVILLE, Ill., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Synata Bio, a U.S.…
HealthEquity CMO Tia Padia Named “Visionary CMO” at MarCom Awards
Award recognizes Padia’s vision to bring client and member experiences to life…
Raleigh Laser & Aesthetics Joins Leading Medical Associations, Elevating Standards in Non-Invasive Skincare
RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Raleigh Laser & Aesthetics…
Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer
Company appoints Anil K. Sood, MD, as inaugural member Company continues to…
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first “Phagogram Day”
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at…
Ben Austin, CFO and COO of SPR Therapeutics, Namedto Crains Cleveland Business 40 Under 40 List
CLEVELAND, Nov. 18, 2024 (GLOBE NEWSWIRE) -- For over 30 years, Crain’s…
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis…
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneer of…
Novo Nordisk A/S – share repurchase programme
Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk…
